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Abstract
Objective To determine the long-term prognostic value of
stress imaging and clinical risk scoring for cardiovascular
mortality in chest pain patients after ruling out acute
coronary syndrome (ACS).
Methods A standard rule-out protocol was performed in
emergency room patients with a normal or non-diagnostic
admission electrocardiogram (ECG) within 6 h of chest
pain onset. ACS patients were identified by troponin T,
recurrent angina and serial ECG. Dobutamine stress
echocardiography (DSE) was performed after ACS was
ruled out. Myocardial perfusion scintigraphy (MPS) was
performed within 6 months in an outpatient setting
according to the physician’s discretion.
Results 524 patients were included. GRACE and TIMI risk
scores were 75 (57– 96) and 1 (0–2) in the rule-out ACS group,
and 89 (74–107) and 2 (1–3) in the ACS group, respectively
(median, interquartile range). Follow-up (median 9.4 (8.9–
10.0) years) was complete in 96%. 350 of 379 rule-out ACS
patients had an interpretable DSE and 52 patients underwent
an MPS. 21 of the rule-out ACS patients (6%) died of a
cardiovascular cause compared with 24 (17%) ACS patients
(p<0.001). For rule-out ACS patients, C-statistics were
0.829 and 0.803 for the GRACE and TIMI scores. In these
patients, DSE and MPS outcome did not predict long-term
cardiovascular mortality. In multivariate analysis, known
chronic heart failure, ACE inhibitor use, and GRACE score
were independent predictors of cardiovascular mortality.
Conclusions TIMI and GRACE score but not DSE and MPS
are accurate predictors of long-term cardiovascular mortality,
even in chest pain patients with a normal or non-diagnostic
electrocardiogram undergoing a rule-out protocol.
Keywords Chest pain . Echocardiography . Stress imaging .
Cardiovascular mortality . GRACE risk score . TIMI risk
score
Introduction
Accurate risk stratification is vital in patients with com-
plaints suggestive of myocardial ischaemia [1, 2]. Although
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ECG and cardiac biomarkers are low-cost tools for
identification of high-risk patients in need of intensive
medical treatment, these tests are hampered by lack of
sensitivity and are therefore insufficient for identifying all
patients at high risk [3]. Exercise testing is widely
performed for diagnostic and prognostic information, but
its additional value is limited [4], and the testing is
unfeasible in patients with an uninterpretable ECG and in
patients unable to exercise [5, 6]. Stress imaging, such as
myocardial perfusion scintigraphy (MPS) or dobutamine
stress echocardiography (DSE), may provide an alternative.
Available studies on prediction models in acute chest pain
patients have a limited follow-up [7–10]. Although reports
on the long-term prognostic value of MPS and DSE are
extensive, they are limited by the selection of primarily
stable patients [11–15]. In a previous prospective study, we
reported an important and independent short-term prognostic
value of DSE in acute chest pain patients with a normal or
non-diagnostic ECG and negative cardiac necrosis markers
[16]. The present study investigates the long-term prognostic
value DSE and MPS in these patients, in comparison to
available clinical risk scores.
Methods
We conducted a prospective, multicentre study in patients
presenting at the emergency room with chest pain as
described earlier [16]. Patients who presented at the
emergency room within 6 h after onset of chest pain and
who had a normal or non-diagnostic ECG were eligible for
inclusion. Excluded were patients younger than 18 years,
patients who were unable to give informed consent, and
patients with any of the following conditions: atrial
fibrillation, conduction disturbances (second or third degree
atrial-ventricular block or new bundle branch block), severe
uncontrolled hypertension (>180/120 mmHg) despite
adequate therapy, severe heart failure, cardiomyopathy,
status after resuscitation, serious non-cardiac disease (e.g.
infection and neoplastic conditions), and pregnancy. The
study was performed in accordance with the principles
set out in the declaration of Helsinki and was approved
by local ethics committees on human research. Patients
remained under observation until at least 12 h after the
onset of symptoms. Evaluation included careful history
taking, physical examination, serial 12-lead ECGs,
continuous rhythm monitoring, and serial cardiac troponin T
measurements. Serial ECGs were recorded according to
protocol directly on admission, after the administration of
sublingual nitrates, and during any new episode of chest pain
while the patient remained under observation and before
discharge. Troponin Twas measured at admission (i.e., within
6 h of chest pain) and at 12 h after the onset of chest pain. After
heart rate) or if other endpoints were not reached at peak
dobutamine dose. Endpoints included severe and/or
extensive new wall motion abnormality, significant
tachyarrhythmias, significant changes on the ECG, severe
chest pain, significant increase or decrease in blood
pressure (>240/120 mmHg or reduction of systolic
pressure >40 mmHg), or any intolerable side effect. A
beta-blocker was administered intravenously to reverse the
side effects, if they did not revert spontaneously and
quickly after stopping the dobutamine infusion. For
purpose of analysis, the left ventricular wall was divided
into 16 segments and scored using a four-point scale (1,
normal; 2, hypokinetic; 3, akinetic; and 4, dyskinetic)
according to current guidelines [17]. A positive DSE was
defined as the occurrence of new wall motion abnormality
in at least one segment and was indicative for myocardial
ischaemia. Myocardial ischaemia was not considered if
akinetic segments at rest became dyskinetic during stress
[18]. The images of the DSE were compared off-line side
by side in quad screen format by two experienced
investigators without knowledge of the patients’ clinical
data. In case of disagreement, a majority decision was
achieved by a third investigator (JHC, OK, RB). The
results were dichotomised as either positive or negative
for ischaemia.
Myocardial perfusion scintigraphy
Myocardial perfusion scintigraphy (MPS) was performed in
an outpatient setting at the physician’s discretion, according
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ruling out an acute coronary syndrome by a negative serial
cardiac troponin T (defined as peak value 0.03 μg/L at 6
and 12 h after the onset of symptoms) and by serial
ECGs, the remaining patients underwent a two-
dimensional echocardiography. In a post-hoc analysis,
all enrolled patients received a clinical score using the
Global Registry of Acute Coronary Events (GRACE) [7]
and Thrombolysis In Myocardial Infarction (TIMI) for
NSTEMI/unstable angina [10]. The full details of the design
and methods of the GRACE and TIMI risk scores have been
previously published (available at www.outcomes-umassmed.
org/grace and www.timi.org, respectively).
Dobutamine stress echocardiography
or echocardiogram
The DSE was performed according to the current guide-
lines [5]: dobutamine was infused intravenously based on
3-minute stages of 10, 20, 30, and 40 μg/kg/min. Atropine
(0.25 to 1 mg intravenously) was given if 85% of the age-
predicted maximal heart rate was not reached (i.e., target
to the guidelines of the American Society of Nuclear
Cardiology [19] using a 2-day stress/rest protocol. A dose
of 500 MBq of technetium-99 m–tetrofosmin was adminis-
tered at rest and at peak exercise. All patients were stressed
with a bicycle ergometer with a starting workload of 50 W,
increasing by 25 W every 2 min. Endpoints for exercise
included achievement of ≥85% of age-predicted heart rate,
recognisable chest pain, and >2-mm ST-segment depres-
sion [20]. All patients fasted both days, and antianginal
medication was discontinued before the exercise test and
restarted after exercise. Gated myocardial single-photon
emission computed tomography was performed with the
patient in a prone position.
Stress and rest perfusion images were scored in consensus
by two experienced nuclear medicine physicians (HJV and
FMvdZ) using a five-point semi-quantitative score for each of
17 myocardial segments. Perfusion defect severity was
classified as normal (0), equivocally abnormal (1), mildly
abnormal (2), moderately abnormal (3), or severely abnormal
(4). Subsequently, summed stress score, summed rest score
(SRS), and the difference between those scores (summed
difference score, SDS) were calculated. SDS≥3 was
considered to indicate myocardial ischaemia. A fixed
defect was defined as a SRS score of ≥3. Mixed defects,
partly reversible (SDS≥3) and partly fixed, were analysed as
reversible. The results were dichotomised as either positive or
negative for ischaemia and either as normal (no perfusion
abnormalities) or abnormal (combined ischaemia and fixed
defects). Assessment was performed blinded to patient data.
Analysis of troponin T
Troponin T levels were determined with an enzyme-linked
immunosorbent assay method on an Elecsys 300 analyser
(Roche Diagnostics, Almere, the Netherlands) using a third-
Follow-up
Endpoint of the study was cardiovascular mortality, defined
as myocardial infarction, life-threatening arrhythmia, or
pulmonary oedema (based on clinical assessment, cardiac
isoenzymes, ECG, or autopsy), or cerebrovascular accident.
Unexpected death without an identified non-cardiac cause
was also classified as cardiovascular death. Information on
mortality was obtained from the National Registry on
Mortality. For cause of death, the patients’ general practi-
tioners were contacted, and letters from hospital files were
obtained, if necessary. Follow-up was complete for 96%
(95% for rule-out ACS patients and 98% for ACS patients).
Median follow-up was 9.4 years (8.9–10.0 years) [9.4 years
(8.9–10.0 years) for rule-out ACS patients and 9.2 years
(8.9–9.9 years) for ACS patients].
Statistical analysis
Continuous variables were expressed as mean ± SD
when normally distributed, and median (interquartile
range) if otherwise, and were compared using student’s
T-test and Mann–Whitney-U test, respectively. Categorical
variables were presented as frequencies, and compared
using the chi-square test. Clinical variables were dicho-
tomised with prospectively defined, clinically relevant
cut-off points to improve readability of the data.
Univariate and multivariate backward conditional Cox
proportional hazard model was used to evaluate the
associations between the outcome measures (primary
endpoint: time to death). The variables incorporated into
the GRACE and TIMI risk scores were excluded from the
multivariate analysis. To estimate the discriminative value of
Grace and TIMI risk scores, we calculated the C-statistic (area
under the receiver operating characteristic curve). Survival
analysis was performed with the Kaplan–Meier method and
the log-rank test was used for comparisons of curves. The
SPSS statistical package (SPSS PASW 18.0 for Windows,
SPSS Inc., Chicago, Illinois) was used for analysis.
Results
The study comprised a total of 557 patients who gave
informed consent. Thirty-three patients had serious non-
cardiac or cardiac diagnoses other than ACS. In the
remaining 524 patients, 145 were diagnosed with ACS
period). These patients were defined as high-risk patients.
The remaining 379 patients with ACS ruled out were
discharged early, i.e. after the observation period. In these
rule-out ACS patients, DSE was performed. Of these, 350
had an interpretable DSE. MPS was performed in 52
patients.
Table 1 shows the baseline characteristics of the entire
cohort of chest pain patients presenting at the emergency
room with a normal or non-diagnostic ECG. ACS
patients were older and more often had a history of
coronary artery disease. The use of beta-blockers and
calcium antagonists was more prevalent in ACS patients
whereas rule-out ACS patients more often had a normal
ECG. DSE was positive in 23 rule-out ACS patients (7%
of 350 interpretable DSE). MPS was abnormal in
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generation assay. A positive result was defined as a level
≥0.03 μg/L, on admission or at 12 h after onset of
symptoms.
(positive serial troponin T ≥ 0.03 μg/L, recurrent angina
and/or dynamic ECG changes during the observation
8 patients (15% of 52 MPS performed), and showed
myocardial ischaemia in 4 patients (7% of 52 MPS
performed). The GRACE risk score was low in both
groups (75 (57–96) in rule-out ACS vs. 75 (57–96) in
ACS patients, as well as TIMI risk scores (1 (0–2) vs. 2
(1–3) (median, (25th, 75th percentiles)), respectively.
Both GRACE and TIMI risk scores were significantly
higher in ACS patients.
During follow-up, death occurred in 78 patients (15%),
43 (11%) in the rule-out ACS group and 35 (24%) in the
ACS group (p<0.001). Causes of death are displayed in
Table 2. Of all deceased patients, 45 (58%) had a
cardiovascular cause of death. In the rule-out ACS group,
21 patients (49% of deaths in this group) died of a
cardiovascular cause compared with 24 (69%) in the ACS
group (p<0.001).
Variables Rule-out ACS (n=379) ACS (n=145) p
Age (years) mean ± SD 56±12 62±11 <0.001
Men 220 (58) 97 (67) 0.064
Diabetes mellitus 36 (10) 20 (14) 0.155
Hypertension 145 (38) 61 (42) 0.424
Current cigarette smoking 141 (37) 44 (30) 0.124
Hypercholesterolaemia 133 (35) 50 (35) 0.896
Family history of CAD 193 (51) 66 (46) 0.268
Documented CADa 80 (21) 43 (30) 0.039
Previous myocardial infarction 59 (16) 26 (18) 0.511
History of chronic heart failure 2 (1) 3 (2) 0.104
Peripheral artery disease 50 (13) 20 (14) 0.835
TIA/CVA 22 (6) 9 (6) 0.861
Medication on admission
Aspirin 123 (33) 59 (41) 0.076
Beta-blocker 104 (27) 59 (41) 0.003
Calcium antagonist 56 (15) 35 (24) 0.011
ACE inhibitor 43 (11) 20 (14) 0.441
Statin 65 (17) 27 (19) 0.692
Baseline ECG category
Normal 228 (60) 56 (39) <0.001
Cardiac imaging results
Positive DES 23/350 (7%)
Abnormal MPS 8/52 (15%)
Reversible perfusion defects on MPS 4/52 (7%)
GRACE risk score (25th, 75th percentiles) 75 (57–96) 89 (74–107) <0.001
TIMI risk score (25th, 75th percentiles) 1 (0–2) 2 (1–3) <0.001
Table 1 Baseline characteristics
according to stratum
aDocumented CAD defined as
prior acute myocardial infarc-
tion, revascularisation, or docu-
mented coronary artery stenosis
≥ 50%) on coronary angiogram.
ACE = angiotensin-converting
enzyme; ACS = acute coronary
syndrome; CAD = coronary
artery disease, CVA = cerebro-
vascular accident; DSE
dobutamine stress echocardiog-
raphy =; MPS = Myocardial
perfusion scintigraphy, TIA =
transient ischaemic attack
Overall
(n=524)
Rule-out ACS
(n=379)
ACS
(n=145)
p
Follow-up 9.4 (8.9–10.0) 9.4 (8.9–10.0) 9.2 (8.9–9.9)
Death (all-cause) 78 (15%) 43 (11%) 35 (24%) <0.001
Time-to-death 6.1 (2.5–7.6) 6.1 (2.5–7.7) 6.0 (2.5–7.6)
Cardiovascular death 45 (58%) 21 (49%) 24 (69%) <0.001
- Sudden unexpected death 10 3 7
- Acute myocardial infarction 6 5 1
- Heart failure 5 1 4
- CVA 3 1 2
- Acute abdominal aortic aneurysm 1 1 0
- Unknown 20 10 10
Table 2 Cause of death accord-
ing to risk group
ACS = acute coronary syn-
drome; CVA = cerebrovascular
accident
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Variables Univariate analysis Multivariate analysis
Point estimate p Point estimate P
Age>65 years 14.61 (4.91–43.45) <0.001
Men 0.65 (0.28–1.55) 0.656
Diabetes mellitus 2.55 (0.86–7.58) 0.092
Hypertension 1.50 (0.64–3.53) 0.356
Current cigarette smoking 1.34 (0.85–2.11) 0.203
Hypercholesterolaemia 0.91 (0.370–2.26) 0.844
Family history of CAD 0.92 (0.39–2.15) 0.838
Documented CADa 5.24 (2.21–12.44) <0.001
Previous myocardial infarction 5.22 (2.21–12.29) <0.001
Known chronic heart failure 14.63 (1.96–109.43) 0.009 10.41 (1.17–92.37) 0.035
Peripheral artery disease 1.68 (0.56–4.99) 0.352
TIA/CVA 4.14 (1.39–12.32) 0.011
Aspirin use 3.60 (1.49–8.67) 0.004
Beta-blocker use 1.34 (0.54–3.32) 0.529
Calcium antagonist use 4.55 (1.92–10.80) 4.547
ACE inhibitor use 4.50 (1.82–11.16) 0.001 4.38 (1.70–11.29) 0.002
Statin use 0.23 (0.03–1.68) 0.146
Normal baseline ECG 0.15 (0.05–0.44) 0.001
Cardiac imaging results
Positive DSE 0.64 (0.09–4.75) 0.660
Abnormal MPS – –
Reversible perfusion defects on MPS – –
GRACE risk scoreb 6.82 (3.88–11.99) <0.001 7.41 (4.05–13.57) <0.001
TIMI risk score c 4.88 (2.07–11.49) <0.001
Table 3 Univariate and
multivariate Cox regression
analysis for cardiovascular
mortality of clinical parameters
and cardiac imaging in rule-out
ACS patients
a Documented CAD defined as
prior acute myocardial infarc-
tion, revascularisation, or docu-
mented coronary artery stenosis
≥ 50%) on coronary angiogram.
ACE = angiotensin-converting
enzyme; ACS = acute coronary
syndrome; CAD = coronary ar-
tery disease, CVA = cerebrovas-
cular accident; DSE =
dobutamine stress echocardiog-
raphy; MPS = Myocardial per-
fusion scintigraphy, TIA =
transient ischaemic attack
b according to GRACE risk
score categorisation of patients
for non–ST-segment elevation
ACS: low (1–108), intermediate
(109–140), and high (141–372)
risk
c according to TIMI risk score
categorisation for unstable angi-
na/NSTEMI, low (0–2), inter-
mediate (3–4), and high (5–7)
risk
Fig. 1 Survival of rule-out ACS
chest pain patients with a normal
or non-diagnostic ECG.
Kaplan-Meier plots are
displayed showing survival
stratified by GRACE risk score
categorisation of patients for
non-ST-segment elevation ACS:
low (1–108), intermediate (109–
140), and high (141–372) risk
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The GRACE and TIMI risk scores demonstrated a very
good discrimination for long-term cardiovascular mortality.
For rule-out ACS patients, C-statistics were 0.829 and
0.803, and for ACS patient C-statistics were 0.807 and
0.715 for the GRACE and TIMI scores, respectively.
Table 3 shows the results of the univariate and
multivariate Cox regression analysis for cardiovascular
mortality of clinical parameters and cardiac imaging. An
age above 65 years, documented coronary artery disease, a
previous myocardial infarction, history of chronic heart
failure, transient ischaemic attack or cerebrovascular
accident, aspirin and ACE inhibitor use, an abnormal
baseline electrocardiogram as well as GRACE and TIMI
score were predictors of cardiovascular mortality. None
of the patients with an MPS suggestive of myocardial
ischaemia (n=4) or abnormal MPS (n=8) had cardiovas-
cular mortality during follow-up. A positive DSE was not
identified as a prognostic marker for cardiovascular
mortality. In multivariate analysis, known chronic heart
failure, ACE inhibitor use, and GRACE score were
independent predictors of cardiovascular mortality.
Figure 1 shows the Kaplan Meier curves stratified by
GRACE risk score categorisation of patients for non–ST-
segment elevation ACS. In patients with intermediate
(109 to 140) and high (141 to 372) GRACE risk scores,
cardiovascular mortality (75% and 23% respectively) was
notably higher than in the low GRACE risk scores (1 to
108) rule-out ACS patients (2%).
Discussion
In our rule-out ACS population of chest pain patients with a
normal or non-diagnostic electrocardiogram, long-term
cardiovascular mortality during a 9-year follow-up was
low (6%), and comparable to previous studies on chest pain
patients without ST elevation on ECG [7–9]. The long-term
cardiovascular prognosis of patients with a positive DSE or
reversible or irreversible defects on MPS was as good as
the prognosis of patients with normal DSE or MPS.
However, GRACE and TIMI risk scores had predictive
values with C-statistics comparable to the values found in
the ACS populations for which they were designed [21,
22], but this is the first study, to our knowledge, to show a
long-term value for these scoring systems in a rule-out ACS
population.
Previous studies have shown a predictive value of DSE
for cardiac adverse events [11, 12]. However, these studies
involved single-centre experiences in very heterogeneous
populations of consecutive patients undergoing DSE.
Moreover, these studies did not evaluate cardiovascular
mortality as a separate event. In another study by Steinberg
[13], DSE was predictive for cardiovascular mortality, but
the population consisted of patients referred for coronary
angiography with mortality rates twice as high as in our
study. In an emergency department setting of patients with
suspected myocardial infarction, MPS was predictive for
cardiac mortality, but again the cardiac mortality rate was
more than twice as high as the cardiovascular mortality in
our study [23]. The absence of a predictive value for DSE
and MPS in our study might thus be related to the selection
of patients with an already apparent low risk of cardiovas-
cular mortality.
There are several limitations to our study. First, we only
studied cardiovascular mortality with no secondary end-
points such as myocardial infarction and revascularisation.
In a previous study, we have shown the strong and
independent short-term predictive value of DSE for these
endpoints in our populations [24]. However, for long-term
risk stratification, mortality endpoints are more relevant as
shown by a continuation of the survival curve [13], in
contrast to converging and flattening curves of combined
endpoints [11, 15].
Second, MPS was only performed in a very small subset
of the population. Nonetheless, with an equally low
cardiovascular mortality rate (4%, data not shown), this
subset is comparable to the entire rule-out ACS cohort.
In conclusion, imaging for inducible myocardial ischae-
mia by DSE and MPS does not predict long-term
cardiovascular mortality in chest pain patients with a
normal or non-diagnostic electrocardiogram after ruling
out ACS. The TIMI and GRACE scores, however, are
accurate predictors in these patients with low long-term
cardiovascular mortality.
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